Global Meropenem Market Overview:
Meropenem is a carbapenem antibiotic, which is active against gram-positive and gram-negative bacteria. Meropenem penetrate bacterial cells by interfering with the synthesis of vital cell wall components, which leads to cell death. Meropenem injection does not work for cold, flu or other viral infections. Taking antibiotics when they are not needed increases the risk of getting an infection which afterwards resists antibiotic treatment. Meropenem is an important option for the empirical treatment of serious bacterial infections in hospitalized patients. Some of the key players profiled in the study are Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Fresenius Kabi (Canada), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Abbott (United States) and GE Healthcare (United States).
On the basis of geography, the market of Meropenem has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Spain, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Strength, the sub-segment i.e. 0.5g will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing awareness towards healthy lifestyle
- Rising prevalence of skin infection across the globe
- Growing use in empirical treatment
- Effective in the treatment of bacterial meningitis
- Inappropriate use can affects adversely
- Increasing healthcare infrastructure in developing countries
- Easy availability of substitutes
March 20, 2019: Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics and On 7th Jan 2019 Takeda has acquired Shire
The companies are exploring the market by adopting mergers & acquisitions, expansions and investments as their preferred strategies. Key players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations.
Target Audience:Manufacturers of pharmaceutical drugs, Suppliers of pharmaceutical drugs, Wholesalers, distributers and retailers of pharmaceutical drugs, Healthcare industry, Research Firms and Governmental bodies
Major Objectives Focused through this Study To define, describe, and forecast the Global Meropenem market on the basis of product  , application [Hospital use, Clinic and Others], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Meropenem market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Spain, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Meropenem industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Spectrum Chemical Manufacturing Corp (United States), Shijiazhuang Pharma (China) and Haikou Pharmaceutical Factory (China).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Meropenem market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.